Lexicon Pharmaceuticals (LXRX)
still isn't what I'd call a household name in biotech, even though the
company has over $1 billion in market capitalization and at least two
solid drug product candidates. With Friday's news of a successful Phase
II study in carcinoid syndrome and the launch of a Phase III study,
Lexicon investors have good reason for a little cheer going into the
weekend.
Please continue here:
Lexicon Pushes On To Phase III
No comments:
Post a Comment